Agustín Ruiz Laza

Director of the Biology Core

University of Texas Health Science Center at San Antonio
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (17)

Year:

2026

Blood biomarkers have emerged as accurate tools for detecting Alzheimer’s disease (AD) pathology, offering a minimally invasive alternative to traditional diagnostic methods such as imaging and cerebrospinal fluid (CSF) analysis. Yet, the logistics surrounding venipuncture for blood collection, although considerably simpler than the acquisition of imaging and CSF, require precise processing and storage specific to AD biomarkers that are still guided by medical personnel. Consequently, limitations in their widescale use in research and broader clinical implementation exist. The DROP-AD project investigates the potential of dried plasma spot (DPS) and dried blood spot (DBS) analysis, derived from capillary blood, for detecting AD biomarkers, including phosphorylated tau at amino acid 217 (p-tau217), glial fibrillary acidic protein and neurofilament light. Here, 337 participants from 7 centers were included, with 304 participants providing paired capillary DPS or DBS and venous plasma samples. We observed strong correlations between DPS p-tau217 and venous plasma p-tau217 ( r S = 0.74, P < 0.001). DPS p-tau217 progressively increased with increasing disease severity, and showed good accuracy in predicting CSF biomarker positivity (area under the curve = 0.864). Similarly, we demonstrated the successful detection of glial fibrillary acidic protein and neurofilament light with strong correlations between DBS and DPS, respectively, using paired venous plasma samples. Notably, the method was also effective in individuals with Down syndrome, a population at high genetic risk for AD but in whom standard blood sampling by venipuncture may be more complicated, revealing elevated biomarkers in those with dementia compared with asymptomatic individuals. The study also explored unsupervised blood collection, finding high concordance between supervised and self-collected samples. These findings underscore the potential of dried blood collection and capillary blood as a minimally invasive, scalable approach for AD biomarker testing in research settings. Yet, further refinement of collection and analytical protocols is needed to fully translate this approach to be viable and useful as a clinical tool.

Year:

2026

Lipidomics offers potential for the early detection of Alzheimer’s disease (AD) and for elucidating the molecular mechanisms driving the progression from mild cognitive impairment (MCI) to AD. In this study, we investigated and validated the association between 139 cerebrospinal fluid (CSF) lipids and MCI-to-AD conversion. We included 400 MCI participants from the Ace Alzheimer Center Barcelona (ACE) cohort, all free of type 2 diabetes, comprising both ATN+ and ATN− individuals. After a median follow-up of 2.1 years, 142 participants progressed to AD dementia. We identified a multi-lipid signature of 11 lipids (including phosphatidylcholines, lysophosphatidylcholines, triglycerides, phosphatidylethanolamines, lysophosphatidylethanolamines and phosphatidylinositols) in CSF, which was associated with increased AD progression (HR = 1.85, 95% CI: 1.53–2.27). This signature was validated in paired plasma samples, a less invasive biofluid (HR = 1.26, 95% CI: 1.04–1.52) and in plasma samples from an external cohort of 189 participants (149 with subjective cognitive decline, 40 with MCI; β = 0.261, 95% CI: 0.022–0.500), demonstrating moderate-to-high predictive accuracy for MCI-to-AD progression. Counterfactual-based mediation analysis revealed that plasma phosphorylated tau-181 mediated up to 47% of the association between the lipid signature and AD dementia, highlighting glycerophospholipid metabolism as a key pathway. Exploratory Mendelian randomisation analyses suggested a potential causal association of lipid signature and AD, with two instrumental single-nucleotide polymorphisms mapped to loci implicated in neurodevelopmental and metabolic regulation (RBFOX1 and CDKAL1). In conclusion, our findings support the growing evidence of lipid metabolism dysregulation as an early marker of AD and identify plasma lipids reflecting CSF profiles that may be promising prognostic markers for AD dementia.

Year:

2025

Neurodegenerative diseases (including Alzheimer’s disease, Parkinson’s disease, Frontotemporal dementia, and Dementia with Lewy bodies) pose diagnostic challenges due to overlapping pathology and clinical heterogeneity. We leveraged proteomic data from more than 21,000 cerebrospinal fluid and plasma samples to develop and validate explainable, boosting-based multi-disease AI classifiers. The models achieved weighted AUCs in the testing datasets of 0.97 for CSF and 0.88 for plasma, equivalent to traditional biomarkers. The model was validated with neuropathological and clinical data, confirming robust generalizability without any retraining. Using zero-shot learning, we classified disease subtypes including autosomal dominant AD and prodromal PD and clarified disease states for those with conflicting clinical information. The model also showed the ability to prioritize cognitively normal individuals at disease risk. This framework enabled the identification and quantification of continuous, individual-level disease probabilities that allow for the quantification of overlap across diseases and co-pathologies within an individual. Through this work, we establish a benchmark computational framework for enhancing diagnostic precision in NDs.

Year:

2025

Cerebrospinal fluid (CSF) amyloid beta (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau181) are well accepted markers of Alzheimer’s disease. We performed a GWAS meta-analysis including 18,948 individuals of European and 416 non-European ancestry. We identified 12 genome-wide significant loci across all three biomarkers, eight of them novel. We replicated the association of CSF biomarkers with APOE , CR1 , GMNC/CCDC50 and C16orf95/MAP1LC3B . Novel loci included BIN1 for Aβ42 and GNA12, MS4A6A, SLCO1A2 with both t-tau and p-tau181, as well as additional loci on chr. 8, near ANGPT1 and chr. 9 near SMARCA2 . We also demonstrated that these variants were not only associated with CSF level of the three biomarkers but also showed significant association with AD risk, disease progression and/or brain amyloidosis. The associated genes are implicated in lipid metabolism independent APOE , as well as autophagy and brain volume regulation driven by t-tau and p-tau181 dysregulation.

Year:

2025

Among the more than 90 identified genetic risk loci for late-onset Alzheimer’s disease (AD) and related dementias, the apolipoprotein E gene ( APOE ) ɛ2/ɛ3/ɛ4 polymorphisms remains the longstanding benchmark for genetic disease risk with a consistently large effect across studies 1–10 . Despite this massive signal, the exact mechanisms for how ɛ4 increases and for how ɛ2 decreases dementia risk is not well-understood. Importantly, recent trials of anti-amyloid therapies suggest less efficacy and higher risks of severe side effects in ε4 carriers 11–13 , hampering the treatment of those with the highest unmet need. To improve our understanding of the genetic architecture of AD in the context of its main genetic driver, we performed genome-wide association studies (GWASs) stratified by ε4 and ε2 carrier status. Such insights may help to understand and overcome side effects, to impact clinical trial enrolment strategies, and to create the scientific basis for targeted mechanism-driven therapies in neurodegenerative diseases.

Year:

2025

INTRODUCTION Hippocampal sclerosis of aging (HS-aging) is frequently present in individuals over 85 who die with dementia. Recent studies suggest that some loci associated with Alzheimer’s disease (AD) may be more related to HS-aging. We aimed to find AD-associated SNPs potentially related to HS-aging. METHODS We assessed the relation of the AD polygenic risk score (AD-PRS) with hippocampal subfield volumes assessed by magnetic resonance imaging (MRI) as HS-by-proxy in 1,130 non-demented participants. We analyzed 1,708 individuals to associate their AD-PRS (83 variants) with AD alongside HS-aging. RESULTS HS-by-proxy measures of fimbria and hippocampal body and head show association with AD-PRS, SHARPIN , GRN and TNIP1 , also after replication. We replicated the stronger AD-PRS association with AD in the presence of HS-aging compared to AD alone. DISCUSSION Results show association between some AD-SNPs and HS-proxy, enriched in immune-brain axis pathways, differentiating HS-aging from AD. This insight aids in understanding their interrelationships and identifying specific therapeutic targets.

Year:

2025

High-throughput proteomic platforms are crucial to identify novel Alzheimer’s disease (AD) biomarkers and pathways. In this study, we evaluated the reproducibility and reliability of aptamer-based (SomaScan® 7k) and antibody-based (Olink® Explore 3k) proteomic platforms in cerebrospinal fluid (CSF) samples from the Ace Alzheimer Center Barcelona real-world cohort. Intra- and inter-platform reproducibility were evaluated through correlations between two independent SomaScan® assays analyzing the same samples, and between SomaScan® and Olink® results. Association analyses were performed between proteomic measures, CSF biological traits, sample demographics, and AD endophenotypes. Our 12-category metric of reproducibility combining correlation analyses identified 2428 highly reproducible SomaScan CSF measures, with over 600 proteins well reproduced on another proteomic platform. The association analyses among AD clinical phenotypes revealed that the significant associations mainly involved reproducible proteins. The validation of reproducibility in these novel proteomics platforms, measured using this scarce biomaterial, is essential for accurate analysis and proper interpretation of innovative results. This classification metric could enhance confidence in multiplexed proteomic platforms and improve the design of future panels.

Year:

2024

Background: Alzheimer’s disease (AD) dementia and mild cognitive impairment (MCI) are currently underdiagnosed in the community, and early detection of cognitive deficits is crucial for timely intervention. FACEmemory®, the first completely self-administered online memory test with voice recognition, has been launched as an accessible tool to detect such deficits. This study aims to investigate the neuropsychological associations between FACEmemory subscores and cognitive composites derived from traditional paper-and-pencil neuropsychological tests and to develop an optimal algorithm using FACEmemory data and demographics to discriminate cognitively healthy (CH) individuals from those with MCI. Methods: A total of 669 participants (266 CH, 206 non-amnestic MCI [naMCI], and 197 amnestic MCI [aMCI]) were included. Multiple linear regression analyses were conducted using a cognitive composite as the dependent variable and FACEmemory subscores and demographic data (age, sex, and schooling) as independent variables. Machine learning models were compared to identify an optimal algorithm for distinguishing between CH and MCI (whole MCI, aMCI, and naMCI). Results: Multiple regression analyses showed associations between FACEmemory scores and the domains of memory (ρ = 0.67), executive functions (ρ = 0.63), visuospatial/visuoperceptual abilities (ρ = 0.55), language (ρ = 0.43), praxis (ρ = 0.52), and attention (ρ = 0.31). An optimal algorithm distinguished between CH and aMCI, achieving a FACEmemory cutoff score of 44.5, with sensitivity and specificity values of 0.81 and 0.72, respectively. Conclusions: FACEmemory is a promising online tool for identifying early cognitive impairment, particularly aMCI. It may contribute to addressing the underdiagnosis of MCI and dementia in the community and in promoting preventive strategies.

Year:

2024

TREM2 encodes a microglial membrane receptor involved in the disease-associated microglia (DAM) phenotype whose activation requires the transmembrane interaction with TYROBP. Mutations in TREM2 represent a high-impact risk factor for Alzheimer’s disease (AD) which turned TREM2 into a significant drug target. We present a bacterial two-hybrid (B2H) system designed for high-throughput screening of modulators for the TREM2-TYROBP transmembrane interaction. In a pilot study, 315 FDA-approved drugs were analyzed to identify potential binding modifiers. Our pipeline includes multiple filtering steps to ensure candidate specificity. The screening suggested two potential candidates that were finally assayed in the human microglial cell line HMC3. Upon stimulation with anti-TREM2 mAb, pSYK/SYK ratios were calculated in the presence of the candidates. As a result, we found that varenicline, a smoking cessation medication, can be considered as a transmembrane agonist of the TREM2-TYROBP interaction.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (109)

Stefanie Heilmann-Heimbach

Head of Laboratory, Research Group Leader

University Hospital Bonn

GERMANY
View details

Ruth Frikke-Schmidt

Professor, Chief Physician, MD PhD DMSc

-

DENMARK
View details

Luis M Real

Profesor

Universidad de Sevilla

SPAIN
View details

Maria Jesús Bullido Gómez-Heras

Researcher

Universidad Autónoma de Madrid

SPAIN
View details

Elena Sánchez-López

Assitant Professor

University of Barcelona

SPAIN
View details

Pau Pastor

Institut Català de la Salut

SPAIN
View details

Daniele Altomare

Scuola universitaria professionale della Svizzera italiana

SWITZERLAND
View details

Eloy Rodriguez-Rodríguez

Instituto de Investigación Marqués de Valdecilla

SPAIN
View details

innocenzo rainero

University of Turin

ITALY
View details

Alex Rovira

Head of Neuroradiology

Hospital Universitari Vall d'Hebron

SPAIN
View details

Henrik Zetterberg

Professor

University of Gothenburg

SWEDEN
View details

Yun Ju Sung

Washington University in St. Louis

UNITED STATES
View details

Harro Seelaar

Neurologist

Erasmus MC

NETHERLANDS
View details

Philippe Amouyel

Full Professor

Centre Hospitalier Régional Universitaire de Lille

FRANCE
View details

Jesper Qvist Thomassen

Senior Scientist

Rigshospitalet

DENMARK
View details

Tony Wyss-Coray

Professor

Stanford University

UNITED STATES
View details

Johannes Kornhuber

-

GERMANY
View details

Amanda Cano

Head of Molecular Biology & Biomarkers program

-

SPAIN
View details

Henne Holstege

Professor

KU Leuven

BELGIUM
View details

Marco Spallazzi

Adjunt professor

University of Parma

ITALY
View details

Markus Nöthen

Professor, Director

University Hospital Bonn

GERMANY
View details

Benedetta Nacmias

University of Florence

ITALY
View details

Laura Ibanez

Assistant Professor

Washington University in Saint Louis School of Medicine

UNITED STATES
View details

Nicholas Seyfried

Professor

Emory University

UNITED STATES
View details

Suzanne Schindler

Associate Professor

Washington University in St. Louis

UNITED STATES
View details

Lucilla Parnetti

Professor of Neurology

University of Perugia

ITALY
View details

Caroline Jonson

University of California, San Francisco

UNITED STATES
View details

Vilmundur Gudnason

Professor

University of Iceland

ICELAND
View details

Pieter Jelle Visser

Karolinska Institutet

SWEDEN
View details

Jordi Pérez-Tur

Coordinador Adjunto al Área Global Vida

Agencia Estatal Consejo Superior de Investigaciones Científicas

SPAIN
View details

Antoni Camins

University of Barcelona

SPAIN
View details

Patrizia Mecocci

Director

Karolinska Institutet

SWEDEN
View details

Caroline Graff

Professor,MD PhD

Karolinska Institutet

SWEDEN
View details

Henna Martiskainen

University of Eastern Finland

FINLAND
View details

Amy Kit Yu Fu

Research Professor

The Hong Kong University of Science and Technology

HONG KONG
View details

Arvid Rongve

Professor

University of Bergen

NORWAY
View details

Jean-Charles Lambert

Head of research unit

INSERM

FRANCE
View details

Bryan Strange

Profesor I3

Universidad Politécnica de Madrid

SPAIN
View details

Betty Tijms

Senior researcher

VU medisch centrum

NETHERLANDS
View details

Simon Laws

Professor

Edith Cowan University

AUSTRALIA
View details

María del Carmen Mañas Padilla

Coordinadora Adjunta Máster en Nueropsicología y Educación

Universidad Internacional de La Rioja

SPAIN
View details

Nancy Yuk-Yu Ip

The Morningside Professor of Life Science

The Hong Kong University of Science and Technology

HONG KONG
View details

Katja Scheffler

Associate Professor

Norwegian University of Science and Technology

NORWAY
View details

John Morris

Professor

Washington University School of Medicine

UNITED STATES
View details

Takeshi Ikeuchi

Professor

Brain Research Institute, Niigata University

JAPAN
View details

Jonathan Vogelgsang

Harvard University

UNITED STATES
View details

Erik Johnson

Assistant Professor

Emory University School of Medicine

UNITED STATES
View details

Meghan Campbell

Washington University in Saint Louis School of Medicine

UNITED STATES
View details

Ciyang Wang

Washington University in St. Louis

UNITED STATES
View details

Geir Selbaek

Professor

University of Oslo

NORWAY
View details

Nil Novau-Ferré

Part-time professor

Universidad Rovira i Virgili

SPAIN
View details

Timothy Hohman

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Pablo Mir

-

SPAIN
View details

Norbert Scherbaum

Professor for Clinical Addiction Research

University of Duisburg-Essen Faculty of Medizin

GERMANY
View details

Tormod Fladby

Professor ll of Neurology

University of Oslo

NORWAY
View details

Margda Waern

University of Gothenburg

SWEDEN
View details

Muhammad Ali

Assistant Professor

Washington University in St. Louis

UNITED STATES
View details

Silke Kern

Professor/ Chief Physician

University of Gothenburg

SWEDEN
View details

Miren Ettcheto

Profesor agregado

University of Barcelona

SPAIN
View details

Andrew Saykin

Professor and Director, Center for Neuroimaging and Indiana Alzheimer's Disease Research Center

Indiana University School of Medicine

UNITED STATES
View details

Eric Dammer

Scientist, Bioinformatics

Emory University

UNITED STATES
View details

Srdjan Djurovic

Professor at University of Oslo

University of Oslo

NORWAY
View details

Sami Heikkinen

Research Director

University of Eastern Finland

FINLAND
View details

Najaf Amin

Associate Professor

University of Oxford

UNITED KINGDOM
View details

Wiesje van der Flier

Scientific director

VU medisch centrum

NETHERLANDS
View details

Peter Holmans

Professor of Biostatistics and Genetic Epidemiology

Cardiff University

UNITED KINGDOM
View details

Ted Wilson

Provost's Assistant Professor of Neuroimmunology & Brain Science

Brown University

UNITED STATES
View details

David M. Holtzman

Washington University School of Medicine

UNITED STATES
View details

Thor Aspelund

Professor

University of Iceland

ICELAND
View details

Dan Rujescu

Head of Clinical Division of General Psychiatry

Medical University of Vienna

AUSTRIA
View details

Alessio Squassina

Dalhousie University

CANADA
View details

Carole Dufouil

Director of research

INSERM

FRANCE
View details

Virginia M-Y Lee

Professor

University of Pennsylvania

UNITED STATES
View details

Robert Perneczky

Professor

Ludwig-Maximilians-Universität München

GERMANY
View details

Martin Ingelsson

Specialist

Uppsala University Hospital

SWEDEN
View details

Hilkka Soininen

Kuopio University Hospital

FINLAND
View details

Gael Nicolas

PUPH

University of Rouen

FRANCE
View details

Riccardo E Marioni

University of Edinburgh

UNITED KINGDOM
View details

Anssi Lipponen

University of Eastern Finland

FINLAND
View details

Mònica Bulló

Professor

Universitat Rovira i Virgili

SPAIN
View details

Patrick Kehoe

Academic , Gestetner Professor of Translational Dementia Research

University of Bristol

UNITED KINGDOM
View details

Silvana Sarria Estrada

Hospital Universitari Vall d'Hebron

SPAIN
View details

Alison Goate

Professor and Chair

Icahn School of Medicine at Mount Sinai

UNITED STATES
View details

Alfredo Ramirez

University of Texas Health Science Center at San Antonio

UNITED STATES
View details

INGVILD SALTVEDT

Professor

Norwegian University of Science and Technology

NORWAY
View details

Dag Aarsland

Professor and Head of Department

King’s College London

UNITED KINGDOM
View details

Daniela Galimberti

Associate Professor

Università degli Studi di Torino

ITALY
View details

Carlos Cruchaga

Professor

Washington University in St. Louis

UNITED STATES
View details

Paul T. Kotzbauer

-

UNITED STATES
View details

Ainhoa García-Sánchez

Profesora de Técnicas de Aprendizaje Automático - Directora de Trabajos de Fin de Máster

Universidad Internacional de La Rioja

SPAIN
View details

Ole A. Andreassen

Oslo University Hospital

NORWAY
View details

Allan I. Levey

Emory University School of Medicine

UNITED STATES
View details

Lucio Tremolizzo

Associate Professor of Neurology

University of Milano-Bicocca

ITALY
View details

Valentina Escott-Price

Professor

Cardiff University

UNITED KINGDOM
View details

Ville Leinonen

Professor

University of Eastern Finland

FINLAND
View details

Lutz Froelich

Head

Zentralinstitut für Seelische Gesundheit

GERMANY
View details

Rebecca Sims

Senior Research Fellow

Cardiff University

UNITED KINGDOM
View details

Barbara Borroni

Docenti di ruolo di IIa fascia

University of Brescia

ITALY
View details

Lars Bertram

Professor of Genome Analytics

University of Lübeck

GERMANY
View details

Jose Luis Royo

University of Malaga

SPAIN
View details

Valborg Gudmundsdottir

Research Assistant Professor

University of Iceland

ICELAND
View details

Mikko Hiltunen

University of Eastern Finland

FINLAND
View details

Cornelia Van Duijn

Professor

University of Oxford

UNITED KINGDOM
View details

Alberto Lleó

Director

Hospital de la Santa Creu i Sant Pau

SPAIN
View details

Erik Stomrud

Lund University

SWEDEN
View details

Adriana Castro-Zavala

Instituto de Investigación Biomédica de Málaga

SPAIN
View details

Sterling Johnson

Professor

University of Wisconsin-Madison

UNITED STATES
View details

Menghan Liu

Washington University in St. Louis

UNITED STATES
View details

Farhad Imam

Assistant Professor

University of California, San Diego

UNITED STATES
View details